{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:50:14Z","timestamp":1777395014153,"version":"3.51.4"},"reference-count":39,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2017,8,29]]},"DOI":"10.3233\/jad-170502","type":"journal-article","created":{"date-parts":[[2017,8,18]],"date-time":"2017-08-18T11:09:43Z","timestamp":1503054583000},"page":"201-210","source":"Crossref","is-referenced-by-count":12,"title":["Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe"],"prefix":"10.1177","volume":"60","author":[{"given":"Anne-Marie","family":"Miller","sequence":"first","affiliation":[{"name":"Medical Gerontology, School of Medicine, Trinity College, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mircea","family":"Balasa","sequence":"additional","affiliation":[{"name":"Global Brain Health Institute, Trinity College Institute of Neuroscience, Trinity College Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[{"name":"Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology, University of Gothenburg, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Gardiner","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, St. James\u2019s Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Rutkowska","sequence":"additional","affiliation":[{"name":"Medical Gerontology, School of Medicine, Trinity College, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[{"name":"Department of Neurology\/Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Neurochemistry Lab and Biobank, Neurocampus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter Jelle","family":"Visser","sequence":"additional","affiliation":[{"name":"Department of Neurology\/Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands"},{"name":"Department of Psychiatry and Neuropsychology, Alzheimer Centre Limburg, Maastricht University Medical Centre, School for Mental Health and Neuroscience, Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt","family":"Winblad","sequence":"additional","affiliation":[{"name":"Department NVS, Karolinska Institute, Centre for Alzheimer Research, Division of Neurogeriatrics, Huddinge, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunhild","family":"Waldemar","sequence":"additional","affiliation":[{"name":"Department of Neurology, Danish Dementia Research Centre, Neuroscience Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Lawlor","sequence":"additional","affiliation":[{"name":"Global Brain Health Institute, Trinity College Institute of Neuroscience, Trinity College Dublin, Ireland"},{"name":"Mercer\u2019s Institute for Successful Ageing, St. James\u2019s Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-170502_ref1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.3233\/JAD-170502_ref3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/jnnp.66.2.184","article-title":"Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer\u2019s disease and frontotemporal dementia","volume":"66","author":"Varma","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-170502_ref4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","article-title":"Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer\u2019s Disease Centers, 2005-2010","volume":"71","author":"Beach","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-170502_ref5","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"New Engl J Med"},{"key":"10.3233\/JAD-170502_ref6","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1212\/WNL.58.5.750","article-title":"Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia","volume":"58","author":"Jack","year":"2002","journal-title":"Neurology"},{"key":"10.3233\/JAD-170502_ref7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrneurol.2009.215","article-title":"The clinical use of structural MRI in Alzheimer\u2019s disease","volume":"6","author":"Frisoni","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-170502_ref8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2217\/bmm.09.83","article-title":"Cerebrospinal fluid biomarkers of Alzheimer\u2019s disease","volume":"4","author":"Fagan","year":"2010","journal-title":"Biomark Med"},{"key":"10.3233\/JAD-170502_ref9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2967\/jnumed.111.096578","article-title":"Effectiveness and safety of 18F-FDG-PET in the evaluation of dementia: A review of the recent literature","volume":"53","author":"Bohen","year":"2011","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-170502_ref10","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1001\/jama.289.16.2094","article-title":"Decreased \u03b2-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer\u2019s disease","volume":"289","author":"Sunderland","year":"2003","journal-title":"JAMA"},{"key":"10.3233\/JAD-170502_ref11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.nbd.2008.10.003","article-title":"Biomarkers of Alzheimer\u2019s disease","volume":"35","author":"Craig-Schapiro","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JAD-170502_ref12","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer\u2019s disease: Revising the NINCDS-ADRDA criteria","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-170502_ref13","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","article-title":"Revising the definition of Alzheimer\u2019s disease: A new lexicon","volume":"9","author":"Dubois","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-170502_ref14","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer\u2019s disease: The IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-170502_ref15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimer Dement"},{"key":"10.3233\/JAD-170502_ref16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer Dement"},{"key":"10.3233\/JAD-170502_ref17","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/gerona\/61.7.755","article-title":"Cerebrospinal fluid amyloid \u03b242 \/ phosphorylated tau ratio discriminates between Alzheimer\u2019s disease and vascular dementia","volume":"61A","author":"deJong","year":"2006","journal-title":"J Gerontol"},{"key":"10.3233\/JAD-170502_ref18","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jalz.2014.03.003","article-title":"The clinical use of cerebrospinal fluid biomarker testing for Alzheimer\u2019s disease diagnosis: A consensus paper from the Alzheimer\u2019s Biomarkers Standardization Initiative","volume":"10","author":"Molinuevo","year":"2014","journal-title":"Alzheimer Dement"},{"key":"10.3233\/JAD-170502_ref19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jalz.2012.11.003","article-title":"Global standardization measurement of cerebral spinal fluid for Alzheimer\u2019s disease: An update from the Alzheimer\u2019s Association Global Biomarkers Consortium","volume":"9","author":"Carrillo","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-170502_ref20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00702-003-0065-z","article-title":"Core biological marker candidates of Alzheimer\u2019s disease \u2013 perspectives for diagnosis, prediction of outcome and reflection of biological activity","volume":"111","author":"Hampel","year":"2004","journal-title":"J Neural Transm"},{"key":"10.3233\/JAD-170502_ref21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000286280","article-title":"Cerebrospinal fluid biomarkers in diagnosing Alzheimer\u2019s disease in clinical practice: An Illustration with 3 case reports","volume":"2","author":"Slats","year":"2010","journal-title":"Case Rep Neurol"},{"key":"10.3233\/JAD-170502_ref22","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","article-title":"CSF biomarkers for incipient Alzheimer\u2019s disease","volume":"2","author":"Blennow","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-170502_ref23","first-page":"610613","article-title":"Lessons from multicentre studies on CSF biomarkers for Alzheimer\u2019s disease","volume":"2010","author":"Mattsson","year":"2010","journal-title":"Int J Alzheimers Dis"},{"key":"10.3233\/JAD-170502_ref24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2217\/bmm.12.46","article-title":"Recommendations to standardize preanalytical confounding factors in Alzheimer\u2019s and Parkinson\u2019s disease cerebrospinal fluid biomarkers: An update","volume":"6","author":"del Campo","year":"2012","journal-title":"Biomark Med"},{"key":"10.3233\/JAD-170502_ref25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jalz.2011.07.004","article-title":"Standardisation of preanalyticical aspects of cerebrospinal fluid biomarker testing for Alzheimer\u2019s disease diagnosis. A consensus paper from the Alzheimer\u2019s Biomarker Standardization Initiative","volume":"8","author":"Vanderstichele","year":"2012","journal-title":"Alzheimer Dement"},{"key":"10.3233\/JAD-170502_ref26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jalz.2014.02.004","article-title":"Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer\u2019s disease","volume":"11","author":"Blennow","year":"2015","journal-title":"Alzheimer Dement"},{"key":"10.3233\/JAD-170502_ref27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fneur.2015.00179","article-title":"A practical guide to immunoassay method validation","volume":"6","author":"Andreasson","year":"2015","journal-title":"Front Neurol"},{"key":"10.3233\/JAD-170502_ref28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1468-1331.2009.02753.x","article-title":"Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe","volume":"17","author":"Hort","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-170502_ref29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2009.1064","article-title":"CSF biomarkers and Incipient Alzheimer\u2019s disease in patients with mild cognitive impairment","volume":"302","author":"Mattson","year":"2009","journal-title":"JAMA"},{"key":"10.3233\/JAD-170502_ref30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1373\/clinchem.2009.134692","article-title":"Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment","volume":"56","author":"Dean","year":"2009","journal-title":"Clin Chem"},{"key":"10.3233\/JAD-170502_ref31","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jalz.2011.10.008","article-title":"Comparison of International Working Group criteria and National Institute on Aging \u2013 Alzheimer\u2019s Association criteria for Alzheimer\u2019s disease","volume":"8","author":"Visser","year":"2012","journal-title":"Alzheimer Dement"},{"key":"10.3233\/JAD-170502_ref32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.tips.2015.03.002","article-title":"Amyloid biomarkers in Alzheimer\u2019s disease","volume":"36","author":"Blennow","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.3233\/JAD-170502_ref33","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000320265","article-title":"A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer\u2019s disease in a memory clinic","volume":"30","author":"Morinaga","year":"2010","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-170502_ref34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2015.08.003","article-title":"Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study","volume":"12","author":"Duits","year":"2016","journal-title":"Alzheimer Dement"},{"key":"10.3233\/JAD-170502_ref35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2011.08753.x","article-title":"Guidelines on oral anticoagulation with warfarin \u2013 Fourth Edition","volume":"154","author":"Keeling","year":"2011","journal-title":"Br J Haematol"},{"key":"10.3233\/JAD-170502_ref36","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/clinchem\/47.10.1776","article-title":"Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values","volume":"47","author":"Sj\u00f6gren","year":"2001","journal-title":"Clin Chem"},{"key":"10.3233\/JAD-170502_ref37","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1212\/WNL.0b013e3182477eed","article-title":"Age and diagnostic performance of Alzheimer disease CSF biomarkers","volume":"78","author":"Mattsson","year":"2012","journal-title":"Neurology"},{"key":"10.3233\/JAD-170502_ref38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jalz.2013.01.010","article-title":"CSF biomarker variability in the Alzheimer\u2019s Association quality control program","volume":"9","author":"Mattsson","year":"2013","journal-title":"Alzheimer Dement"},{"key":"10.3233\/JAD-170502_ref39","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/156720510791383796","article-title":"The cerebrospinal fluid amyloid beta42\/40 ratio in the differentiation of Alzheimer\u2019s disease from non-Alzheimer\u2019s dementia","volume":"7","author":"Spies","year":"2010","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-170502_ref41","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jalz.2015.09.009","article-title":"Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of \u03b2-amyloid (1-42) in human cerebrospinal fluid","volume":"12","author":"Bittner","year":"2016","journal-title":"Alzheimers Dement"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-170502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:04:45Z","timestamp":1777370685000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-170502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":39,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-170502","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,29]]}}}